Review Volume 12, Issue 5 pp 4660—4672
Adiponectin in renal fibrosis
- 1 The Third Affiliated Hospital of Southern Medical University; Zunyi Medical University, Guangzhou, Guangdong Province, China
- 2 The First People’s Hospital of Foshan, Foshan, Guangdong Province, China
- 3 Guangzhou Eighth People's Hospital, Guangzhou, Guangdong Province, China
- 4 Panyu Central Hospital, Panyu, Guangzhou, Guangdong Province, China
received: August 12, 2019 ; accepted: January 25, 2020 ; published: February 17, 2020 ;https://doi.org/10.18632/aging.102811
How to Cite
Copyright © 2020 Jing et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Renal fibrosis is an inevitable consequence of parenchymal scarring and is the common final pathway that mediates almost all progressive renal diseases. Adiponectin, a hormone produced by adipose tissue, possesses potent anti-insulin, anti-inflammatory, and anti-fibrotic properties. Reportedly, adiponectin serves as an important messenger that facilitates complex interactions between adipose tissue and other metabolically related organs. In recent years, a growing body of evidence supports adiponectin involvement in renal fibrosis. These studies provide a deeper understanding of the molecular mechanism of action of adiponectin in renal fibrosis and also offer a potential preventive and therapeutic target for renal fibrosis. In this review, the physiological role of adiponectin is briefly introduced, and then the mechanism of adiponectin-mediated renal fibrosis and the related signaling pathways are described. Finally, we summarize the findings regarding the clinical value of adiponectin in renal fibrotic diseases and prospected its application potential.